ProAxsis is delighted to have been shortlisted for a Business Eye First Trust Award for the second year running. Having been …
Type and hit ENTER
November 18, 2019
Posted by David Ribeiro
ProAxsis was delighted to support the recent School of Pharmacy Undergraduate Awards at Queen’s University, Belfast. For the second year running, the …
October 25, 2019
Posted by David Ribeiro
ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman of the company’s Board of Directors with immediate …
October 25, 2019
Posted by David Ribeiro
Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the British Lung Foundation (BLF) …
June 3, 2019
Posted by Webmaster
The potential benefits of ProAxsis’ novel ProteaseTag® Active Proteinase 3 Immunoassay will be discussed at the Winter meeting of the British Thoracic …
November 26, 2018
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces …
September 20, 2018
Posted by David Ribeiro
ProAxsis will today be presenting new data on its highly novel active neutrophil elastase (NE) point-of-care test, NEATstik®, at the European …
September 18, 2018
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces …
August 2, 2018
Posted by David Ribeiro
ProAxsis will be presenting three abstracts at the COPD 11 Conference, which takes place between June 20th-21st 2018 in Birmingham, UK. …
June 18, 2018
Posted by David Ribeiro
ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for …
June 4, 2018
Posted by David Ribeiro
ProAxsis Limited has received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative …
June 1, 2018
Posted by David Ribeiro
ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society Conference, which takes place …
May 2, 2018
Posted by David Ribeiro
ProAxsis is proud to be collaborating with Dr. Gunnar Schroeder and Prof. Cliff Taggart from the School of Medicine, Dentistry and …
March 6, 2018
Posted by David Ribeiro
Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of NEATstik®, the company’s novel …
February 15, 2018
Posted by David Ribeiro
ProAxsis Limited (www.proaxsis.com) today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay. This novel technology …
January 8, 2018
Posted by Webmaster
ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes place between December 6th-8th at …
December 5, 2017
Posted by Webmaster
Having reached the first anniversary following relocation to its new purpose-built laboratory on the Catalyst Inc. site in the Titanic Quarter of …
November 21, 2017
Posted by Webmaster
ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference, which takes place between …
October 30, 2017
Posted by Webmaster
ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate the company’s …
October 27, 2017
Posted by Webmaster
ProAxsis today announces that the company has appointed Diagenics Limited as the distributor for its ProteaseTag® Active Neutrophil Elastase Immunoassay in Great …
September 14, 2017
Posted by Webmaster
ProAxsis Ltd today announces that the company has signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, …
September 11, 2017
Posted by Webmaster
ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes place between September 9th-13thin …
September 6, 2017
Posted by Webmaster
ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care test for measuring active …
September 4, 2017
Posted by Webmaster
Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for its ProteaseTag® technology, via …
July 24, 2017
Posted by Webmaster
ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the European Cystic Fibrosis Society …
June 19, 2017
Posted by Webmaster
Dr David Ribeiro, CEO of ProAxsis, will be attending the Anglonordic Life Sciences Conference, taking place in London this week, and will …
May 30, 2017
Posted by Webmaster
ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the most recent edition of …
May 17, 2017
Posted by Webmaster
ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s University of Belfast for …
May 10, 2017
Posted by Webmaster
ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes place between May 19th-24th …
May 5, 2017
Posted by Webmaster
Dr David Ribeiro, CEO of ProAxsis, will be attending the Bio-Europe Spring meeting, taking place in Barcelona on March 20th-22nd 2017, and will …
March 6, 2017
Posted by Webmaster
ProAxsis Limited (www.proaxsis.com) is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis …
January 25, 2017
Posted by Webmaster
In a significant new study, a team at the University of Dundee has shown for the first time that sputum neutrophil elastase (NE) activity, …
December 23, 2016
Posted by Webmaster
ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay was identified as a …
December 8, 2016
Posted by Webmaster
ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference in Orlando, Florida. The …
October 26, 2016
Posted by Webmaster
ProAxsis were this week delighted to host His Royal Highness, the Duke of York, at their new laboratory facilities within the Concourse …
October 19, 2016
Posted by Webmaster
ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase …
September 30, 2016
Posted by Webmaster
Dr David Ribeiro, CEO of ProAxsis, will be attending the 16th Biotech in Europe Forum, taking place in Basel on September 27th-28th 2016, …
September 23, 2016
Posted by Webmaster
ProAxsis (www.proaxsis.com) is delighted to have been featured in the latest edition of Business Eye, Northern Ireland’s premium business magazine. This article …
September 16, 2016
Posted by Webmaster
ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland support. Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, …
June 20, 2016
Posted by Webmaster
ProAxsis will be attending the BIO 2016 conference, taking place at the Moscone Convention Center in San Francisco between June 5th-9th 2016. The …
June 2, 2016
Posted by Webmaster
ProAxsis will this week be presenting further data on its ProteaseTag® Active Neutrophil Elastase (NE) Immunoassay, at the American Thoracic Society Conference in …
May 16, 2016
Posted by Webmaster
ProAxsis is delighted to announce that Dr Kelly Moffitt has joined the company in the role of Senior Project Manager, and will …
May 9, 2016
Posted by Webmaster
ProAxsis CEO David Ribeiro was interviewed by ProActive Investors UK. Watch the video on Stock-Tube
May 4, 2016
Posted by Webmaster
ProAxsis is pleased to announce the appointment of Sarah Ganniclefft to the newly created role of Sales and Marketing Manager. Sarah …
April 20, 2016
Posted by Webmaster
Dr David Ribeiro, CEO of ProAxsis, will be attending the 10th anniversary Biotrinity conference, taking place in London on April 25th-27th 2016, and …
April 19, 2016
Posted by Webmaster
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com
RECENT NEWS
-
November 18, 2019
ProAxsis shortlisted for Small Business of the Year Award
-
October 25, 2019
ProAxsis supports next generation of scientists
-
October 25, 2019
ProAxsis welcomes Professor Stephen Smith as new Chairman
LATEST TWEETS
ProAxsis
RT @ProfJDChalmers: Incredible news for bronchiectasis patients and clinicians- positive results for a novel anti-inflammatory therapy- Sig…
19 days ago - ProAxsisRT @ProfJDChalmers: We have known that neutrophils and elastase predicts exacerbations and disease severity in bronchiectasis for several y…
20 days ago - ProAxsisIt’s great to see NEATstik highlighted as a key biomarkers monitoring tool in #bronchiectasis by @AlibertiStefano a… https://t.co/guSpjEZqld
37 days ago - ProAxsis@ProAxsis will be closed for the Christmas Holidays from 23rd December until Monday 6th January. Any queries should… https://t.co/zkH0CaIvaq
65 days ago - ProAxsisCopyright © 2016-2018 - ProAxsis - All rights reserved.
Grid Blog - Wide | ProAxsis